Skip to main content

Advertisement

SpringerLink
Log in

A Review of the Selected and Newer Antiseizure Medications Used in Childhood Epilepsies

  • Review Article
  • Published:
Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

There have been additions of newer antiseizure medications in the armamentarium of clinicians for the management of epilepsy. The newer antiseizure medications have advantages of better tolerability, lesser adverse effects, and minimal drug interactions in comparison with conventional antiseizure medications. However, high cost and availability are concerns. There are also peculiar pharmacokinetic and pharmacodynamic considerations for the pediatric age, particularly in the context of age-dependent electroclinical syndromes and precision-based medicine. This review attempts to provide a comprehensive and pragmatic update on newer antiseizure medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2004;45:401–9.

    Article  CAS  Google Scholar 

  2. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1261–73.

    Article  CAS  Google Scholar 

  3. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1000–15.

    Article  CAS  Google Scholar 

  4. Epidiolex prescribing information. Available at: Epidiolex prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf. Accessed on 24 July 2020.

  5. Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19:38–48.

    Article  CAS  Google Scholar 

  6. Xcopri (cenobamate tablets) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf. Accessed on 10 March 2020.

  7. Cenobamate prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf. Accessed on 24 July 2020.

  8. Onfi prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203993s005lbl.pdf. Accessed on 1 Feb 2020.

  9. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA; OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77:1473–81.

  10. Patsalos PN, St Louis EK. The epilepsy prescriber’s guide to antiepileptic drugs. 3rd ed. Cambridge: Cambridge University Press; 2018.

    Book  Google Scholar 

  11. Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b, f]azepine-5-carboxamide derivatives. J Med Chem. 1999;42:2582–7.

    Article  CAS  Google Scholar 

  12. Sperling MR, Abou-Khalil B, Harvey J, et al. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia. 2015;56:244–53.

    Article  CAS  Google Scholar 

  13. Aptiom (eslicarbazepine acetate) prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf. Accessed on 1 Feb 2020.

  14. Abou-Khalil BW. Update on antiepileptic drugs 2019. Continuum (Minneap Minn). 2019;25:508–36.

    Google Scholar 

  15. Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors. Ann Neurol. 1994;35:229–34.

    Article  CAS  Google Scholar 

  16. Felbamate prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020189s022lbl.pdf. Accessed on 1 Feb 2020.

  17. Sachdeo R, Wagner ML, Sachdeo S, et al. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate. Epilepsia. 1999;40:1122–8.

    Article  CAS  Google Scholar 

  18. Wagner ML, Graves NM, Leppik IE, et al. The effect of felbamate on valproic acid disposition. Clin Pharmacol Ther. 1994;56:494–502.

    Article  CAS  Google Scholar 

  19. St Louis EK , Patsalos PN.The epilepsy prescriber’s guide to Antiepileptic Drugs. Cambridge: Cambridge University Press; 2018.

  20. Koubeissi MZ, Azar NJ. Epilepsy board review: a comprehensive guide. New York: Springer; 2017.

    Book  Google Scholar 

  21. Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:2243–54.

    Article  CAS  Google Scholar 

  22. Nabbout R, Mistry A, Zuberi S; FAiRE, DS Study Group, et al. Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2019;77:300–8.

  23. Highlights of Fenfluramin prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202088s001lbl.pdf. Accessed on 24 July 2020.

  24. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998;39:5–17.

    Article  CAS  Google Scholar 

  25. Curia G, Biagini G, Perucca E, Avoli M. Lacosamide a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23:555–68.

    Article  CAS  Google Scholar 

  26. Sake JK, Hebert D, Isojärvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs. 2010;24:1055–68.

    Article  CAS  Google Scholar 

  27. Briviact (brivaracetam) prescribing information. Available at: https://www.briviacthcp.com/briviact-PI.pdf. Accessed on 24 July 2020.

  28. Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56:1890–8.

    Article  CAS  Google Scholar 

  29. Stiripental highlights of prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf. Accessed on 24 July 2020.

  30. Tiagabine prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020646s016lbl.pdf. Accessed on 24 July 2020.

  31. Kälviäinen R, Nousiainen I, Mäntyjärvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology. 1999;53:922–6.

    Article  Google Scholar 

  32. Toggweiler S, Wieser HG. Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of drug intake. Seizure. 2001;10:420–3.

    Article  CAS  Google Scholar 

  33. Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia. 2009;50:184–94.

    Article  CAS  Google Scholar 

  34. Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia. 2009;50:195–205.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Kennedy Krieger Institute and Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA

    Samata Singhi

  2. Pediatric Epilepsy, Epilepsy Center, Department of Neurology/Neurological Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44195, USA

    Ajay Gupta

Authors
  1. Samata Singhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ajay Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SS: Design, data collection, writing; AG: Critical revisions of intellectual content. AG is the guarantor of this paper.

Corresponding author

Correspondence to Samata Singhi.

Ethics declarations

Conflict of Interest

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singhi, S., Gupta, A. A Review of the Selected and Newer Antiseizure Medications Used in Childhood Epilepsies. Indian J Pediatr 88, 993–999 (2021). https://doi.org/10.1007/s12098-021-03857-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-021-03857-8

Keywords

Search

Navigation